ArticleEFSA journal. European Food Safety Authority2025
Safety of lacto-N-tetraose (LNT) produced by a derivative strain (
Article in EFSA journal. European Food Safety Authority, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Safety of lacto-N-triose II as a novel food pursuant to Regulation (EU) 2015/2283.EFSA journal. European Food Safety Authority · 2026Article
- Safety of 3'-sialyllactose (3'-SL) sodium salt produced with a derivative strain (EFSA journal. European Food Safety Authority · 2026Article
- Safety of 6'-sialyllactose (6'-SL) sodium salt produced with a derivative strain (EFSA journal. European Food Safety Authority · 2026Article
- Safety of lacto-N-tetraose (LNT) produced by a derivative strain (EFSA journal. European Food Safety Authority · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on lacto-N-tetraose (LNT) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) LNT, but it also contains lacto-N-triose II, d-lactose, LNT-fructose isomer and a small fraction of other related saccharides. The NF is produced by fermentation with a genetically modified strain (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.